来迪派韦/索磷布韦联合或不联合利巴韦林在基因1型丙型肝炎患者中的安全性与疗效,包括既往 Simeprevir/索磷布韦治疗失败失代偿期肝硬化患者
本研究分析2个肝病中心30例既往SIM/SOF±RBV治疗12周未获SVR的基因1型丙型肝炎患者,再以LDV/SOF±RBV治疗12-24周。总体27/30(90%)获SVR,耐受性良好,最常见不良事件为疲乏、头痛、失眠和恶心,2例Child B级肝硬化患者因静脉曲张出血和腹痛住院,无治疗中断或死亡。
要点
- 既往SIM/SOF±RBV治疗失败的基因1型丙型肝炎患者,再以LDV/SOF±RBV治疗总体SVR为27/30(90%)。
- 30例中26例(86%)有肝硬化,其中16例(62%)为失代偿期Child B或C级。
- 治疗耐受性良好,37%无不良事件,2例Child B级肝硬化患者住院,无中断治疗或死亡。
核心结论
- LDV/SOF±RBV单一片剂固定剂量复方对既往SIM/SOF治疗失败的患者有效且耐受性良好,包括失代偿期肝硬化及肝移植后丙型肝炎复发者。
研究设计与样本
- 来自2个肝病中心联合治疗队列的数据分析,共纳入30例既往接受SIM/SOF±RBV治疗12周未获SVR、后接受LDV/SOF±RBV再治疗的患者。
- LDV/SOF±RBV疗程12-24周,由治疗肝病医生酌情决定。
主要发现
- 30例中23例(77%)为男性,77%为白人,26例(87%)为基因1a型。
- 26例(86%)有肝硬化,其中16例(62%)为失代偿期Child B或C级肝硬化。
- 3例为肝移植后丙型肝炎复发患者。
- 总体27/30(90%)获SVR。
- 治疗耐受性良好,37%报告无不良事件;最常见不良事件为疲乏、头痛、失眠和恶心。
临床怎么用
- 作者结论认为LDV/SOF±RBV对既往SIM/SOF治疗失败的患者有效且耐受性良好,包括失代偿期肝硬化及肝移植后丙型肝炎复发者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination therapy of simeprevir (SIM)/sofosbuvir (SOF) is an approved treatment for hepatitis C genotype (gen) 1 with overall SVR12 rate of 85%-95%. The single tablet fixed-dose combination of ledipasvir (LDV)/SOF is also approved for gen 1 with sustained virologic response at 12 weeks (SVR12) rates ≥95%. No data are available on the efficacy of retreatment with LDV/SOF in patients who failed initial treatment with SIM/SOF. AIM: To evaluate the efficacy of retreatment with LDV/SOF ± ribavirin (RBV) in gen 1 patients who had previously failed treatment with SIM/SOF. METHODS: Data from a combined treatment cohort of 2 hepatology centres, which included patients previously treated with SIM/SOF ± RBV for 12 weeks but failed to achieve SVR and then underwent retreatment with LDV/SOF ± RBV, were analysed (n = 30). LDV/SOF ± RBV was administered for 12-24 weeks based on the discretion of the treating hepatologist. RESULTS: Of the 30 patients, 23 (77%) were male, 77% were Caucasian and 26 (87%) were gen 1a. 26 (86%) had cirrhosis, of which 16 (62%) had decompensated, Child's class B or C cirrhosis. Three patients were liver transplant recipients with recurrent hepatitis C. Overall, 27/30 (90%) achieved SVR. Treatment was well tolerated with 37% reporting no adverse events. The most common adverse events were fatigue, headache, insomnia and nausea. Two patients with Child's B cirrhosis required hospitalization during treatment for variceal haemorrhage and abdominal pain respectively. However, no treatment discontinuations or deaths occurred. CONCLUSION: Single tablet fixed-dose combination LDV/SOF ± RBV is efficacious and well tolerated in patients who previously failed treatment with SIM/SOF, including those with decompensated cirrhosis and recurrent hepatitis C following liver transplantation.
引用
- Modi AA, Nazario HE, Gonzales GR, et al. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir. Aliment Pharmacol Ther. 2018. PMID: 29569736. doi:10.1111/apt.14604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。